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Brain disorders remain one of the deﬁning challenges of modern medicine and among the most poorly served with
new therapeutics. Advances in human neurogenetics have begun to shed light on the genomic architecture of
complex diseases of mood, cognition, brain development, and neurodegeneration. From genome-wide association
studies to rare variants, these ﬁndings hold promise for deﬁning the pathogenesis of brain disorders that have
resisted simple molecular description. However, the path from genetics to new medicines is far from clear and can
take decades, even for the most well-understood genetic disorders. In this review, we deﬁne three challenges for the
ﬁeld of neurogenetics that we believe must be addressed to translate human genetics efﬁciently into new
therapeutics for brain disorders.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2015.04.027Despite pockets of success (e.g., multiple sclerosis) and
periodic spurts of optimism, most drugs for neuropsychiatric
disorders used in clinical practice today are based on mech-
anisms identiﬁed serendipitously many years ago (1). Human
genetics holds the potential for a more mechanistic and
causally linked approach to identify therapeutic hypotheses
and to prioritize drug discovery programs (2). Together with
progress in basic neuroscience and technologies to measure
human brain function (3), we are now in a position to address
historical shortcomings in neuroscience drug discovery—
evidence for disease causality of targeted mechanisms in
humans and a means to identify disease-relevant brain
circuitry in humans.
There are four speciﬁc advantages to using human genetics
and genomics in central nervous system drug research and
development (R&D): 1) less bias toward established hypoth-
eses, 2) an emphasis on human biology, 3) a statistical
framework to establish causality, and 4) the potential for
patient selection to maximize response and clinical beneﬁt.
Traditionally, the bias in industry is to work on hypotheses
based on animal models assumed to be relevant to speciﬁc
clinical symptoms (e.g., forced swim test for depression and
elevated plus maze for anxiety) or on serendipitous human
neuropsychopharmacology (e.g., the dopamine hypothesis in
schizophrenia, the serotonin hypothesis in depression, or the
glutamate hypothesis in just about everything). Human genet-
ics has the potential to overcome this tyranny of old ideas
through less biased, genome-wide approaches to identify
novel mechanisms and by being ab initio based on human
phenotypes. Starting drug discovery with human genotypes
and phenotypes averts the risk of pursuing pathways of
ultimately nondemonstrable causal relevance to human dis-
ease before expensive clinical trials. Moreover, technological
advances have made generation of human genome-wide data
far simpler, and analytic principles and approaches are0 & 2016 Society of Biological Psychiatry. This is an open access a
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SEE COMMENTARYcreating a theoretical framework to understand the variability
of common human genetic variation that minimizes spurious
or irreproducible ﬁndings.
After the theoretical concept of genome-wide association
studies (GWAS) was ﬁrst presented (4), analyses of large-scale
cohorts estimated the threshold for genome-wide signiﬁcance
in European ancestry at p , 7.2 3 1028 (5). In subsequent
studies of larger cohorts and across different phenotypes, this
threshold has generally held up well, in that the association
signals with p values below genome-wide signiﬁcance can be
considered robust and unlikely to become nonsigniﬁcant as
cohort size increases further (6). Although the effect size for
most robustly identiﬁed common variants is small, and even in
aggregate across loci identiﬁed variants can explain only a
small amount of phenotypic variance, GWAS have been clearly
shown to identify risk genes above noise. This statistical
robustness is a remarkable and sometimes overlooked
advantage of GWAS over other high-throughput “omics”
approaches in an era that is plagued by a high degree of
concern over the reproducibility of published ﬁndings (7,8).
Once statistically robust mechanisms have been identiﬁed
through human genetics, it becomes possible to identify
biomarkers that are rooted in causal pathways and can be
incorporated into the drug discovery process from the begin-
ning of a program.
Although these advantages are signiﬁcant, there are also
important hurdles in the systematic exploitation of new disease
loci for the discovery and development of novel therapeutics. In
this review, we present an industry perspective on key chal-
lenges and outline a path from locus to therapeutic hypothesis
that is amenable to established, targeted medicinal chemistry
approaches and testable in clinical trials. The methods, advan-
tages, disadvantages, and current status of various human
genetics approaches to neuropsychiatric disease have been
reviewed extensively elsewhere (9–12); We focus here on article under the CC BY-NC-ND license
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emerging knowledge. The three key challenges we see are 1)
getting from (the right) phenotype to locus, 2) converting
identiﬁcation of a genetic locus into mechanistic disease
insight, and, arguably the most demanding, 3) translating
knowledge of disease mechanism into a therapeutic hypothesis
(Figure 1).
CHALLENGE NO. 1: FROM PHENOTYPE TO LOCUS
Cohort Size Matters, but Are We Selecting the Right
Phenotypes?
Large cohorts of thousands of individuals are necessary for
adequately powered GWAS. Although no guarantee for suc-
cess (13), the availability of large sample sizes for meta-
analyses has resulted in the identiﬁcation of many novel
robust loci for neuropsychiatric disorders such as schizophre-
nia and Alzheimer’s disease (14,15). To analyze multiple
cohorts for the same disorder, it is often necessary to relax
eligibility criteria with regard to phenotypic ascertainment and
disorder deﬁnitions. Although this “lumper” approach comes
at the expense of phenotypic homogeneity, the increase in
statistical power has enabled a breakthrough for numerous
neuropsychiatric phenotypes. One concern of lumping phe-
notypes together is the potential to introduce pathogenic
heterogeneity. However, efforts to date have failed to demon-
strate that patient cohorts with more homogeneous pheno-
types based on psychopathology alone or circuitry-based
measurements (also known as subphenotypes or endopheno-
types) reﬂect more homogeneous disease etiology or under-
lying genetic architecture that would make the identiﬁcation of
disease loci more likely (16–18). The lack of demonstrable
genetic subarchitecture could change as the size of well-
phenotyped patient cohorts increases to levels comparable to
case-control cohorts aimed at identifying susceptibility loci for
traditional disease categories. At the same time, molecular
cross-disorder analyses of schizophrenia, bipolar disorder,
major depressive disorder, autism spectrum disorders, and
attention-deﬁcit/hyperactivity disorder with genome-wide data
have revealed substantial genetic correlation among these
phenotypes (19) and identiﬁed several shared risk loci (20).
Thus, it is the genetic risk variants that provide commonality
across multiple diagnostic categories.
Despite the identiﬁcation of shared risk loci across neuro-
psychiatric diagnoses, it is unclear to what degree current
disease deﬁnitions used to recruit individuals into GWAS are
relevant to the phenotypes that are probed in interventionalPhenotype to locus
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translational psychiatric genetics. Here we outline different
scenarios that caution against an oversimpliﬁed extrapolation
from susceptibility loci to clinical endpoints suitable for drug
registration. We further discuss complementary approaches to
deﬁne relevant phenotypes for drug discovery and
development.
Susceptibility, Severity, and Trajectory
Most phenotypes analyzed in clinical GWAS are aimed at
identifying loci that predispose to disease. Typically, neuro-
psychiatric cohorts consist of patients meeting psychopatho-
logic criteria based on DSM-IV or DSM-5 (21,22) or ICD-10
(23). Cohorts meeting criteria are compared with matched
control populations, and the resulting case-control compar-
ison attempts to ﬁnd disease variants associated with disease.
This emphasis on disease susceptibility in genetic studies
contrasts with most efﬁcacy end points in central nervous
system clinical trials, which assess disease severity or disease
progression (Figure 2). Measures of disease severity and
progression are typically required for new drug registration
with regulators because they serve as proxies for medically
relevant impact on patients’ lives and function. Variation at
susceptibility loci may or may not inﬂuence disease severity or
progression. Even perfectly targeted investigational drugs
derived from susceptibility loci may not produce detectable
effects on the severity or course of disease. One such example
is the apolipoprotein E locus—the strongest and best estab-
lished genetic susceptibility factor for late-onset Alzheimer’s
disease (24). The apolipoprotein E ε4 variant associated with
susceptibility to late-onset Alzheimer’s disease has little, if
any, effect on disease progression when individuals fulﬁll the
clinical criteria of dementia or mild cognitive impairment
(25,26). In such instances, trials to prevent progression as
early as possible, or even delay initial clinical manifestation,
will likely be required to demonstrate efﬁcacy of compounds
acting on disease-causing mechanisms (27,28). In the case of
psychosis, longitudinally phenotyped cohorts are only now
being recruited to understand better the genetic architecture
of disease susceptibility, severity, recurrence, and progression
over many years (29).
For drug discovery, genetic loci and mechanisms associ-
ated with disease severity and progression are at least as
important as those associated with disease susceptibility. It
will be essential to determine the role of susceptibility variants
in more deeply and longitudinally phenotyped cohorts to help
deﬁne precisely for whom, when, and for how long novelFigure 1. A path to apply human
genetics to drug discovery. [Brain
image and crystal structure of H1
receptor with doxepin (60) reproduced
from Wikimedia Commons (61,62)].
mRNA, messenger RNA.
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Figure 2. Schematic representation of disease stages. Each stage
(susceptibility, trajectory, and treatment response) can be conceptualized
as a separate, medically relevant phenotype for human genetics studies. To
date, most genetic studies have focused on disease susceptibility.
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intermediate phenotypes such as determined by neuroimag-
ing. Speciﬁcally, now that we are becoming successful at
identifying loci through lumping, we need to take these loci
back to more deeply phenotyped cohorts to deﬁne the effect
of genetic variants on disease severity and trajectory.
Response to Standard of Care
An additional approach to deconstructing disease phenotypes
is to classify patients on the basis of their response to
approved and widely used medications. Many different scales
for treatment resistance and side-effect proﬁles are used
across neuropsychiatric disorders in clinical trials (30,31). A
key practical consideration for medicines development is the
extent to which a new drug can offer clinical beneﬁt beyond
the current standard of care. Even if approved, payers in all
markets increasingly demand evidence for substantial beneﬁt
above standard of care to justify coverage and reimbursement
(32). Given that the market is replete with inexpensive generic
drugs for important neuropsychiatric disorders such as schiz-
ophrenia, bipolar disorder, anxiety disorders, and major
depressive disorder, many efﬁcacy trials for new drug candi-
dates are designed in an adjunctive setting to test for beneﬁt
beyond standard of care. Parenthetically, this adjunctive
setting is rarely investigated in preclinical studies in rodent
or primate models creating a signiﬁcant translational gap.
This indirect approach to stratiﬁed medicine based on
nonresponse or partial response to standard of care can be
used to deﬁne phenotypes for genetic analyses. Speciﬁcally,
the classiﬁcation of response to an intervention with selective
pharmacologic agents itself can be considered a biologically
robust phenotype. For example, response to antidepressants
has been shown to be a substantially heritable trait (33). The
available cohorts needed to identify loci for antidepressant
response are not yet in the required range of several thousand
individuals (34). Given that sizable cohorts with hundreds and
sometimes thousands of patients are being recruited for late-
stage clinical trials, deﬁning the genetics of drug response
remains an area with considerable potential for drug discovery.
Such an effort requires collaboration across companies and652 Biological Psychiatry April 15, 2016; 79:650–656 www.sobp.org/jconsortia. However, the collection and analysis of DNA
samples, which would enable the construction of large-scale
cohorts to study response variability, is not routine in every
clinical trial. Looking forward, new medicines development will
beneﬁt from a much stronger emphasis on deﬁning the
neurogenomics of drug response or nonresponse for any
given diagnostic category.
Domain-Based Phenotypes
In many areas of neuropsychiatric disease, objective clinical
criteria are not available to establish diagnosis and assess
disease trajectory. Classiﬁcation of mental disorders has
historically been based on the diagnostic reliability of symp-
tom-based, descriptive psychopathology. In many instances,
such nosology may lack biological validity. One effort to
connect neuropsychiatric disease classiﬁcation to underlying
biological processes is the Research Domain Criteria frame-
work proposed by the U.S. National Institute of Mental Health
(35). The concept is to create a biologically more valid
classiﬁcation of mental disorders, and central to the Research
Domain Criteria framework is interrogation of neural circuit
function, connectivity, and network activity associated with
core domains of psychopathology. Examples include the
linkage of working memory to sustained activity in the
prefrontal cortex (36) and the correlation of amygdala
response with fearful stimuli and anxiety disorders (37).
Identiﬁcation of neural circuit endophenotypes is attractive
given the more objective, quantitative, and increasingly stand-
ardized paradigms in neuroimaging (38,39). Ideally, these
quantitative measures will be associated with disease-
relevant neurofunctional domains that can then serve as traits
for genetic analyses. However, caution is warranted because
the degree to which any given circuit endophenotype or
neurofunctional domain measurement is robustly heritable (or
genetically associated), reversible, and related to functional
improvement remains unknown. Any medicines documented
to have an impact on neurofunctional domains must ultimately
provide beneﬁt recognized by patients, providers, regulators,
and payers. We need a much more systematic dissection of
neurofunctional domains, association with genetic variation,
standardization of measurement modalities, and assessment
of the impact of existing and novel drugs in the coming years
to accelerate the relevance of domain-based phenotyping for
drug discovery.
For therapeutics development, the promise of the domain-
based approach is identiﬁcation of novel pharmacology
coupled to neurofunctional domains rooted in human genetic
variation. To date, practical examples of the utility of such an
approach at scales required for large phase 3 studies are
limited. As one example of this domain-based approach,
Papassotiropoulos et al. (40) conducted a GWAS in .2500
healthy volunteers of aversive memory and used bioinformatic
pathway analyses to implicate the histamine H1 receptor gene.
The authors demonstrated an acute effect of diphenhydramine
(which, among other mechanisms, is an antagonist at H1
receptors) on aversive, but not on positive or neutral, memory
in a single-dose, double-blind, placebo-controlled crossover
study in healthy volunteers. Although it remains to be seen if
this observation can be extrapolated to conditions withournal
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traumatic stress disorder, the approach provided a proof of
principle for a population genetics–based nomination of drug
targets for neuropsychological domains.CHALLENGE NO. 2: FROM LOCUS TO DISEASE
MECHANISM
Using Big Data
Once robust loci have been identiﬁed, the next step consists
of interpreting these genetic variations for their molecular
impact on gene and organ system function (Figure 1). One
approach to derive novel hypotheses in silico for disease
mechanisms consists of systematic computational analyses,
such as transcriptomics from relevant human tissues, literature
mining, and pathway analyses. Many of these analyses take
advantage of large-scale data available in the public domain.
The activities we prioritize are 1) mapping the “causal” gene
for each locus, 2) determining the functionality of identiﬁed
polymorphisms and genes, and 3) assessing druggability of
implicated gene products and their proximate pathways. We
describe the ﬁrst two stages in detail and how we approach
target and pathway identiﬁcation.
From Locus to Gene
Identifying the implicated gene for each locus can range from
straightforward to extremely complex if the lead variant with
the lowest p value points to a large genomic region with many
annotated genes. Genetic distance (i.e., the gene in highest
linkage disequilibrium with the locus) as well as detectable
messenger RNA levels in relevant tissue are among the most
useful criteria. In addition, we consider biological plausibility
based on our best understanding of a trait or phenotype.
When candidate genes have been mapped, at the present time
we deprioritize loci implicating genes that do not encode
proteins because they are much more challenging to inves-
tigate further for functionality and are typically not amenable to
traditional small-molecule chemical modulation. However, as
molecular approaches to modify RNA species advance and
we are increasingly able to deﬁne pathways inﬂuenced by
microRNAs and other RNAs, we envision expanding our net to
capture non–protein coding loci.
Functionality of Polymorphism and Gene
One of the most direct means by which a polymorphism can
affect gene functionality is by changing the amino acid
sequence of the expressed protein. However, very few loci
are nonsynonymous variants. Arguably the next best possi-
bility is a genetic variation that alters gene expression. Thus, a
next useful step is using transcriptomics data in conjunction
with genome-wide genotyping. This area is one of the most
actively developing ﬁelds as more and more multi-omics data
sets are being generated on a population basis. As is
becoming standard in most large GWAS publications, at the
present time we test all associated variants of interest for
allele-speciﬁc effects on mRNA expression levels (expression
quantitative trait locus). The advent of RNA sequencing–based
data makes this a high-throughput, data-rich analysis thatBiological Pprovides excellent dynamic range and sensitivity as well as
information on splicing, editing, and strandedness that can
have a strong bearing on deﬁning the molecular impact of a
given genetic variant (41). One important data set across many
different tissues is being generated at the present time by the
Genotype-Tissue Expression Project (42). In the future, it will
be essential to expand this analysis to tissue and homoge-
neous cell populations from donors with speciﬁc diagnoses
and neurofunctional domain phenotypes. Such efforts are
underway in autism (43) and schizophrenia (44,45) and should
be duplicated across all major neuropsychiatric diseases.
From Risk Genes to Novel or Reﬁned Biological
Pathways
As mentioned earlier, an important limitation in GWAS ﬁndings
is the small effect size of risk variants. However, if cohort sizes
are large enough to identify many risk genes simultaneously, a
key advantage of GWAS emerges—the identiﬁcation of bio-
logical risk pathways. Although pathways are only as informa-
tive as the underlying depth of biological evidence that deﬁne
them, they are particularly powerful when derived from human
genetics data pointing toward disease causation. Pathway
analyses have been applied successfully to several disorders
and corroborated or reﬁned based on known mechanisms. For
example, pathway analysis has pointed to novel candidate
mechanisms such as the innate immune system in Alzheimer’s
disease and inﬂammatory bowel disease (46,47). Likewise, the
recently published GWAS of schizophrenia has validated two
long-standing neuropsychopharmacologic hypotheses—the
dopamine D2 receptor and N-methyl-D-aspartate receptor
pathways (15)—while also pointing to novel mechanisms such
as calcium channel signaling that were not previously priori-
tized for this disease (48).
Druggability
With a gene (or ideally pathway) and some understanding of
the molecular lesion, the next step is to examine the impli-
cated genes for druggability of the gene product itself or a
proximate pathway. This assessment consists of two main
parts: an assessment of physicochemical properties of drug
candidates for absorption and distribution (49) and structure-
based approaches to predict potential binding sites. These
topics are reviewed in more detail elsewhere (50).CHALLENGE NO. 3: DETERMINING HOW MUCH
BIOLOGICAL EVIDENCE IS NEEDED FOR A GOOD
DRUG TARGET ORIGINATING FROM GENETICS
Once robust loci have been analyzed, have been contextual-
ized with other “omics” data, and point to a mechanistic
hypothesis, the real challenge begins. This challenge consists
of deﬁning the minimal amount of experimental validation
necessary to invest fully in a new mechanism with medicinal
chemistry and clinical trials. This early validation process is not
well deﬁned in industry at the present time. Traditionally, new
drug targets have many years of existing literature available to
understand key biological mechanisms in greater depth than
new genetically derived targets. If we expect the same amount
of data for targets from human genetics, progress will faltersychiatry April 15, 2016; 79:650–656 www.sobp.org/journal 653
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follow up on the rich substrate of emerging genetic loci. As it
stands, the biopharmaceutical industry (and ﬁeld as a whole) is
struggling to cope with the large number of disease-
associated genetic loci. We tackle the translation of genetic
hypotheses into therapeutic hypotheses from two different
and ruthless angles: kill fast and kill many. It will be many years
before some (it is hoped many) of these novel hypotheses
survive and are tested in clinical trials, and acceleration
requires generation and prioritization of biological evidence
to support translation of loci into drug targets.
Clinical Stratiﬁcation Informed by Human Genetics:
A Step Toward Precision Medicine
In addition to using human genetics to derive novel neuro-
biological hypotheses of disease, one can analyze longitudinal
cohorts for deeper genotype-phenotype studies. Such geno-
typed cohorts can be particularly powerful when they inter-
rogate important endophenotypes such as connectivity deﬁcits
in schizophrenia (51) or span the typical age range of initial
disease manifestation (e.g., adolescence in schizophrenia).
Such cohort analysis can reﬁne or even test emerging neuro-
biological hypotheses of disease, provide clues for a genetically
deﬁned responder subgroup, or point to the time for therapeutic
intervention. The last point can be critical to guide clinical drug
development because most human genetics studies point to
risk factors of disease causation and might best be therapeuti-
cally addressed as early in the disease course as possible.
Such genotype-phenotype analyses need not be based on
exactly the same risk variants (which are typically of small effect
and intronic or intergenic) that ﬁrst implicated the speciﬁc gene.
As the identiﬁcation and cataloging of exonic variants proceeds
rapidly as a result of advances in massively parallel sequencing
(52), we will increasingly have rare variants available that are
often more readily interpretable and informative given their
stronger impact on gene function. Patients or healthy subjects
who carry these variants can provide extremely valuable
insights into disease susceptibility or resilience mechanisms
(e.g., the role of the amyloid precursor protein gene in
Alzheimer’s disease) (53,54), but they require very large recall-
able cohorts with dense genotype and phenotype data.
Translation Requires Ruling Hypotheses Out Rather
Than Accumulating “Converging” Evidence
We have argued in this review for more and better data sets to
support the molecular dissection of neuropsychiatric disease
loci. Yet, eventually there needs to be a tipping point where we
no longer look to build or generate a hypothesis and ﬁnd
additional “converging” evidence, but rather focus on disprov-
ing or otherwise deprioritizing a genetically driven hypothesis.
Such falsiﬁcation need not be related to the role of a genetically
identiﬁed mechanism in the disease process but can be speciﬁc
to drug R&D. For example, one of the most consistent loci in
several neuropsychiatric disorders is CACNA1C (20), which
encodes the α1C subunit of the L-type voltage-gated Ca21
channel (CaV1.2). This channel is a therapeutic target for many
long-approved Ca21 channel blockers in the heart and vascular
smooth muscle, and rare mutations are associated with severe
cardiovascular and central nervous system phenotypes (55,56).654 Biological Psychiatry April 15, 2016; 79:650–656 www.sobp.org/jOne can anticipate that broad modulation of CaV1.2 will
produce substantial cardiac and vascular effects that are
undesirable. From a neuroscience drug discovery perspective,
it will be essential to determine if this channel or its pathway can
be modulated selectively in the brain to enable a sufﬁciently
broad therapeutic index that avoids cardiovascular effects.
Although there is no evidence at the present time that L-type
Ca21 channel modulation is of therapeutic beneﬁt in neuro-
psychiatric disorders, this step needs to occur for the Ca21
channel hypothesis to become an attractive drug target. If such
selectivity cannot be achieved, no matter how strong the
genetic signal, this is not an attractive mechanism to carry
forward and should be deprioritized as a drug target. Although
there can be a strong incentive in the form of publication
potential to produce new evidence that weakly supports a
therapeutic hypothesis, there remains insufﬁcient stimulus to
produce deﬁnitive data that nullify a therapeutic hypothesis. We
need a much greater, incentivized commitment to value “neg-
ative” data that is squarely aimed at ruling out therapeutic
hypotheses and reduce incentives for proliferating subtle hints
or tangential support across myriad hypotheses.
Building a New Collaboration Paradigm Between
Academia and Industry
Human genetics evidence is exploding at a rate that surpasses
traditional incremental increases in biological knowledge. This
expansion in human genetics information demands novel
ways to conduct early translational experiments and requires
that such experiments be carried out on a much greater scale
and with faster tempo. Many academic laboratories have
specialized expertise in the physiology of speciﬁc gene
products and pathways, and the pharmaceutical industry is
in a good position to provide tools such as experimental
compounds and samples from subjects in drug studies.
However, substantial time and energy are spent (and arguably
wasted) in circumlocution around whether a newly identiﬁed
locus, genetic variation, or pathway has therapeutic potential.
Instead, expanded efforts are needed for public/private col-
laboration that enable rapid execution of go/no-go experi-
ments. For execution of a new translational paradigm, it will be
essential that involved academic laboratories, at least for this
undertaking, move away from aiming for elegant biological
stories that mature over many years and accept the desired
high attrition at this stage. Such an approach is challenged by
the current model where downstream publications and funding
require promising positive data. Industry must invest by
substantially supporting the human genetics studies and
associated validation of new targets and pathways.
Such support needs to consider the incentives and goals of
several groups, which include large pharmaceutical compa-
nies, small biotechnology companies, academic laboratories,
and consortia. Large pharma is primarily incentivized to bring
new revenue-generating products to the market, and this aim
is aligned, through regulators and payers, with providing
meaningful medicines that address health needs. To the extent
that drugs based on human genetics lead to streamlined
clinical studies, larger clinical effects, and a more favorable
reception by patients and payers, large pharmaceutical com-
panies stand to meet their goal. For small biotechnologyournal
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therapeutics targeting deﬁned genetic diseases such as cystic
ﬁbrosis, fragile X syndrome, and Duchenne muscular dys-
trophy, and the generation of meaningful neurogenomics data
sets will provide an opportunity for smaller companies to
discover and develop new medicines that target a more
restricted patient population. For individual academic labora-
tories, ﬁndings that reveal novel biology for publication and
advance of a mechanistic program of research are the
proximal incentive. Consortia have a typical goal to build
infrastructure or data sets that are not achievable by individual
laboratories or companies, and they can act as “honest
brokers.” The incentives of consortia often consist of demon-
strating synergistic advances across sectors, institutions, or
laboratories and thus can be very powerful when industry and
academia come together in public/private partnerships (57,58).CONCLUSIONS: IS OPTIMISM WARRANTED OR IS
THIS ANOTHER ROUND OF WISHFUL THINKING?
The current and expected future availability of many new robust
loci as starting points for new neuroscience drug targets
presents a remarkable opportunity. However, the promise alone
is insufﬁcient given the stark reality of the steady decrease in
the number of new drugs approved per billion dollars spent on
R&D (59). Can neurogenomics change the equation? We are
bullish, but key questions remain. When is the “omics” evidence
sufﬁcient to reach a translational tipping point where one can
advance from hypothesis generation mode to hypothesis kill-
ing? How much biological evidence is necessary to warrant
admission to the classic industry R&D pipeline and investment
in medicinal chemistry programs and clinical trials? Can we
scale up early biological validation experiments to follow up on
a sufﬁcient number of genetic hypotheses? Can we work
toward incentivizing and scaling biological validation and
invalidation within academia? There is ultimately one metric
on which we will be judged as a proxy for improved therapeutic
options for patients: more approved medicines based on novel
mechanisms and meaningful added medical beneﬁt.ACKNOWLEDGMENTS AND DISCLOSURES
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